{"id":"siil-live-attenuated-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site pain"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL6068369","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine contains live, attenuated influenza viruses that are not capable of causing disease but can still trigger an immune response, providing protection against future infections. The immune system recognizes the weakened viruses as foreign and mounts a response, producing antibodies and immune cells that can recognize and fight the virus. This immune response helps to protect against future infections with the same or similar strains of the influenza virus.","oneSentence":"SIIL Live Attenuated Influenza Vaccine works by exposing the body to a weakened form of the influenza virus to stimulate an immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:36.937Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention"}]},"trialDetails":[{"nctId":"NCT01797029","phase":"PHASE3","title":"A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh","status":"COMPLETED","sponsor":"PATH","startDate":"2013-02","conditions":"Influenza","enrollment":1761},{"nctId":"NCT01854632","phase":"PHASE3","title":"Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal","status":"COMPLETED","sponsor":"PATH","startDate":"2013-05","conditions":"Influenza","enrollment":1761},{"nctId":"NCT01625689","phase":"PHASE2","title":"Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine","status":"COMPLETED","sponsor":"PATH Vaccine Solutions","startDate":"2012-06","conditions":"Influenza","enrollment":309}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SIIL Live Attenuated Influenza Vaccine","genericName":"SIIL Live Attenuated Influenza Vaccine","companyName":"PATH","companyId":"path","modality":"Biologic","firstApprovalDate":"","aiSummary":"SIIL Live Attenuated Influenza Vaccine works by exposing the body to a weakened form of the influenza virus to stimulate an immune response. Used for Influenza prevention.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}